OncoMatch/Clinical Trials/NCT06817161
Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:
Is NCT06817161 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies transcutaneous auricular vagus nerve stimulation for ovarian carcinoma.
Treatment: transcutaneous auricular vagus nerve stimulation — Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage IIB, III, IIIC, IV (FIGO)
FIGO stage ≥ IIB
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06817161 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB or III or IIIC or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages